Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making - 02/02/18

Doi : 10.1016/j.rcl.2017.10.007

Petar Duvnjak, MD ^a,^b, Ariel A. Schulman, MD ^c, Jamie N. Holtz, MD ^a, Jiaoti Huang, MD, PhD ^d,^e, Thomas J. Polascik, MD ^c,^e, Rajan T. Gupta, MD ^a,^c,^e,^⁎
^a Department of Radiology, Duke University Medical Center, DUMC Box 3808, Durham, NC 27710, USA
^b Department of Radiology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
^c Division of Urologic Surgery, Department of Surgery, Duke Prostate Center, Duke University Medical Center, DUMC Box 2804, Durham, NC 27710, USA
^d Department of Pathology, Duke University Medical Center, DUMC Box 3712, Durham, NC 27710, USA
^e Duke Cancer Institute, DUMC Box 3917, Durham, NC 27710, USA

^∗Corresponding author. Department of Radiology, Duke University Medical Center, DUMC Box 3808, Durham, NC 27710.Department of RadiologyDuke University Medical CenterDUMC Box 3808DurhamNC27710

Résumé

Meaningful changes to the approach of prostate cancer staging and management have been made over the past decade with increasing demand for high-quality multiparametric MR imaging (mpMRI) of the prostate. This article focuses on the evolving paradigm of prostate cancer staging, with emphasis on the role of mpMRI on staging and its integration into clinical decision making. Current prostate cancer staging systems are defined and mpMRI's role in the detection of non–organ-confined disease and how it has an impact on the selection of appropriate next steps are discussed. Several imaging pitfalls, limitations, and future directions of mpMRI also are discussed.

Le texte complet de cet article est disponible en PDF.

Keywords : Prostate cancer, Multiparametric MR imaging (mpMRI), Staging

Plan

Key points

Introduction

Overview of prostate cancer staging and clinical nomograms

Integration of multiparametric MR imaging into clinical algorithms and staging systems

Detection and Characterization of Prostate Cancer with Multiparametric MR Imaging

Role of Multiparametric MR Imaging in Clinical Staging

Extraprostatic Extension

Seminal Vesicle Invasion

Nodal and Metastatic Staging

Imaging pitfalls and limitations of multiparametric MR imaging staging

Impact of multiparametric MR imaging on clinical decision making and future directions

	This project was performed at the Departments of Radiology, Pathology, and Surgery at Duke University Medical Center.
	There is no external or internal funding for this project. This article is not under consideration elsewhere.
	Financial Disclosures/Conflicts of Interest relevant to this submitted work: Dr R.T. Gupta has no financial disclosures or conflicts of interest related to this work. Dr R.T. Gupta does serve as a consultant to Bayer Pharma AG and Invivo Corp. Dr R.T. Gupta also serves on the Speakers Bureau for Bayer Pharma AG. Dr P. Duvnjak, Dr A.A. Schulman, Dr J.N. Holtz, Dr J. Huang, and Dr T.J. Polascik have no conflicts of interest.

Export

Vol 56 - N° 2

P. 239-250 - mars 2018 Retour au numéro

Article précédent

Multiparametric MR imaging of the Prostate : Interpretation Including Prostate Imaging Reporting and Data System Version 2
Alessandro Furlan, Amir A. Borhani, Antonio C. Westphalen

| Article suivant

MR Imaging for Prostate Cancer Screening and Active Surveillance
Sasha C. Druskin, Katarzyna J. Macura

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making - 02/02/18

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL